ES2178634T3 - Peptidos analogos de cnp y su utilizacion. - Google Patents
Peptidos analogos de cnp y su utilizacion.Info
- Publication number
- ES2178634T3 ES2178634T3 ES92101621T ES92101621T ES2178634T3 ES 2178634 T3 ES2178634 T3 ES 2178634T3 ES 92101621 T ES92101621 T ES 92101621T ES 92101621 T ES92101621 T ES 92101621T ES 2178634 T3 ES2178634 T3 ES 2178634T3
- Authority
- ES
- Spain
- Prior art keywords
- ser
- arg
- gly
- phe
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101800000060 C-type natriuretic peptide Proteins 0.000 abstract 1
- 102400001025 CNP-22 Human genes 0.000 abstract 1
- 101800000457 CNP-22 Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
SE PRESENTAN NUEVOS PEPTIDOS REPRESENTADOS POR LA FORMULA GENERAL: Y LAS SALES DE ADICION ACIDAS FISIOLOGICAMENTE ACEPTABLES DE LOS MISMOS; DONDE (A) REPRESENTA H-, H-GLY, H-LYS-GLY, H-SER-LYS-GLY, H-LEU-SER-LYS-GLY, H-GLY-LEU-SER-LYS-GLY, H-SER, H-SER-SER, H-ARG-SER-SER, H-ARG-ARG-SER-SER, H-LEU-ARG-ARG-SER-SER, H-SER-LEU-ARG-ARG-SER-SER; (B) REPRESENTA H-CYS O PMP; (C) REPRESENTA PHE-, PC LANDA-PHE, PF-PHE, PNO SUB 2-PHE O CHA; (D) REPRESENTA ILE, VAL, AIB, TLEU, GLY O LEU; (E) REPRESENTA LYS O ARG; (F) REPRESENTA ILE, LEU O MET; (G) REPRESENTA SER O ALA; (H) REPRESENTA MET O GLN; (I) REPRESENTA -OH, -ASN-OH, -ASN-SER-OH, -ASN-SER-PHE-OH, -ASN-SER-PHE-ARG -OH O -ASN-SER-PHE-ARG-TYR-OH; Y EL SIMBOLO "..." REPRESENTA UN ENLACE DE DIFULSURO; SIEMPRE Y CUANDO 1) ALFA-HANP, 2) ALFA-HANP (7-28) Y 3) CNP-22 SEAN EXCLUIDOS DEL ALCANCE DE ESA FORMULA GENERAL. TAMBIEN SE PRESENTAN LOS AGENTES SUPRESORES DEL CRECIMIENTO DE LAS CELULAS MUSCULARES SUAVES VASCULARES QUE CONTIENEN ESOS PEPTIDOS COMO INGREDIENTES EFECTIVOS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1132191 | 1991-01-31 | ||
JP3254066A JP2809533B2 (ja) | 1991-01-31 | 1991-06-28 | Cnp類似体ペプチド |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2178634T3 true ES2178634T3 (es) | 2003-01-01 |
Family
ID=26346733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92101621T Expired - Lifetime ES2178634T3 (es) | 1991-01-31 | 1992-01-31 | Peptidos analogos de cnp y su utilizacion. |
Country Status (6)
Country | Link |
---|---|
US (1) | US5434133A (es) |
EP (1) | EP0497368B1 (es) |
JP (1) | JP2809533B2 (es) |
AT (1) | ATE219103T1 (es) |
DE (1) | DE69232636T2 (es) |
ES (1) | ES2178634T3 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6360394A (en) * | 1993-03-03 | 1994-09-26 | Mayo Foundation For Medical Education And Research | Vasonatrin peptide and analogs thereof |
US5665704A (en) * | 1993-11-12 | 1997-09-09 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5846932A (en) * | 1993-11-12 | 1998-12-08 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US6525022B1 (en) | 1993-11-12 | 2003-02-25 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
KR100691545B1 (ko) * | 1998-09-28 | 2007-03-09 | 산텐 세이야꾸 가부시키가이샤 | 나트륨 이뇨 펩티드를 유효 성분으로하는 누액 분비 촉진또는 각결막 장해 치료용 점안제 |
DE19903087A1 (de) * | 1999-01-27 | 2000-08-10 | Forssmann Wolf Georg | Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern |
IL142118A0 (en) * | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
WO2004087059A2 (en) * | 2003-03-26 | 2004-10-14 | The University Of Texas | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding |
DK1638443T3 (da) * | 2003-06-20 | 2011-02-07 | Mayo Foundation | Isoformer af hjerne-natriuretisk peptid |
EP3620530A1 (en) | 2004-03-31 | 2020-03-11 | Kazuwa Nakao | Composition for increasing body height |
ES2465141T3 (es) | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
HUE039448T2 (hu) | 2004-04-21 | 2018-12-28 | Alexion Pharma Inc | Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására |
US7795221B2 (en) | 2006-03-30 | 2010-09-14 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
DK2001518T3 (da) | 2006-03-30 | 2013-10-07 | Palatin Technologies Inc | Cykliske natriuretiske peptidfremstillinger |
US8580746B2 (en) | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
MX2009001459A (es) * | 2006-08-08 | 2009-02-19 | Mayo Foundation | Polipeptidos diureticos y natriureticos. |
PT2765139T (pt) * | 2007-07-20 | 2017-07-14 | Mayo Foundation | Polipéptidos natriuréticos |
WO2009046873A1 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Combined use of vasonatrin and gastrin-i as a therapeutic agent |
WO2009036448A2 (en) * | 2007-09-15 | 2009-03-19 | Mayo Foundation For Medical Education And Research | Natriuretic peptide receptor-c agonists |
AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
WO2009086126A2 (en) * | 2007-12-21 | 2009-07-09 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
HUE032582T2 (en) * | 2009-05-20 | 2017-09-28 | Biomarin Pharm Inc | Variants of C-type natriuretic peptide |
US20120208756A1 (en) | 2009-07-23 | 2012-08-16 | Igisu Co., Ltd | Composition for external preparation for skin |
RU2502519C2 (ru) * | 2009-08-27 | 2013-12-27 | Кёко ЭНДО | Терапевтическое средство для лечения ринита |
WO2012013597A1 (de) * | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren |
US9266939B2 (en) | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
BR112013018679B1 (pt) * | 2011-01-21 | 2022-04-12 | Igisu Co. Ltd. | Agente para o tratamento da alopecia e uso de um peptídeo natriurético do tipo c |
WO2012118042A1 (ja) * | 2011-02-28 | 2012-09-07 | 独立行政法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
CN103906761B (zh) | 2011-08-30 | 2016-12-21 | 梅约医学教育与研究基金会 | 利钠多肽 |
WO2013058833A1 (en) | 2011-10-19 | 2013-04-25 | Enobia Canada Limited Partnership | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
US9611305B2 (en) | 2012-01-06 | 2017-04-04 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
CN104059154B (zh) * | 2014-05-06 | 2017-09-29 | 中国人民解放军第四军医大学 | 一种新的具有抗心力衰竭作用的钠尿肽嵌合体cnaac |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
AU2016211447B2 (en) | 2015-01-28 | 2021-09-23 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
US9907834B2 (en) * | 2015-07-30 | 2018-03-06 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
KR20180029255A (ko) | 2015-07-31 | 2018-03-20 | 가부시키가이샤 이기스 | Cnp 고리형 펩티드 및 그 고리형 펩티드를 포함하는 의약품, 외용제 및 화장료 |
KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ(tnsalp)酵素補充療法に有効な投薬計画の特定 |
JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
AU2016365751B2 (en) | 2015-12-08 | 2023-12-21 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat osteoarthritis |
WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
WO2017173413A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
WO2018035420A1 (en) | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
CN110719786A (zh) | 2017-03-31 | 2020-01-21 | 阿雷克森制药公司 | 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法 |
JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 糖タンパク質の製造 |
WO2024086680A2 (en) | 2022-10-21 | 2024-04-25 | Eli Lilly And Company | Long-acting natriuretic peptides and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496544A (en) * | 1983-11-10 | 1985-01-29 | Washington University | Atrial Peptides |
JPH0672157B2 (ja) * | 1984-08-29 | 1994-09-14 | 味の素株式会社 | 新規ペプチド |
EP0232078A3 (en) * | 1986-01-31 | 1990-03-14 | Merck & Co. Inc. | Peptides having anf activity |
EP0292256A3 (en) * | 1987-05-19 | 1990-10-03 | Merck & Co. Inc. | Peptides having anf activity |
US4935492A (en) * | 1987-12-24 | 1990-06-19 | California Biotechnology Inc. | Cyclic analogs of atrial natriuretic peptides |
CA1339210C (en) * | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
DK380288D0 (da) * | 1988-07-07 | 1988-07-07 | Novo Industri As | Hidtil ukendet peptider |
EP0478797B1 (en) * | 1990-04-20 | 1995-04-12 | Hisayuki Matsuo | Novel physiologically active peptide originating in hog |
JP2801079B2 (ja) * | 1990-11-14 | 1998-09-21 | サントリー株式会社 | Anp関連新規ペプチド |
-
1991
- 1991-06-28 JP JP3254066A patent/JP2809533B2/ja not_active Expired - Lifetime
-
1992
- 1992-01-31 AT AT92101621T patent/ATE219103T1/de not_active IP Right Cessation
- 1992-01-31 DE DE69232636T patent/DE69232636T2/de not_active Expired - Lifetime
- 1992-01-31 US US07/828,450 patent/US5434133A/en not_active Expired - Lifetime
- 1992-01-31 EP EP92101621A patent/EP0497368B1/en not_active Expired - Lifetime
- 1992-01-31 ES ES92101621T patent/ES2178634T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0497368A1 (en) | 1992-08-05 |
US5434133A (en) | 1995-07-18 |
DE69232636T2 (de) | 2002-12-05 |
JPH069688A (ja) | 1994-01-18 |
JP2809533B2 (ja) | 1998-10-08 |
EP0497368B1 (en) | 2002-06-12 |
ATE219103T1 (de) | 2002-06-15 |
DE69232636D1 (de) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2178634T3 (es) | Peptidos analogos de cnp y su utilizacion. | |
CO4750841A1 (es) | Compuestos ciclicos, inhibidores de la adhesion | |
ES2071292T3 (es) | Soluciones inyectables estables de factor viii. | |
ES2054017T3 (es) | Metodo para combatir pneumocystis carinii. | |
NO905472L (no) | Insulinanaloger fra menneske og blandinger som inneholderdem. | |
ES2054842T3 (es) | Analogo del factor viii, procedimiento de preparacion y composicion farmaceutica que lo contiene. | |
CY1110927T1 (el) | Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων | |
NO880494L (no) | Syntetiske nonapeptid- og decapeptidanaloger av lhrh som er anvendelige som lhrh-antagonister. | |
ES2041832T3 (es) | Dispositivos para contacto,durante el uso, con un flujo de sangre. | |
DE69329651D1 (de) | Wässrige arzneizusammensetzung, welche das menschliche wachstumshormon enthält | |
ES2137182T3 (es) | Derivados recombinantes del factor viii humano. | |
DE69021335D1 (de) | Wachstumshormonfusionsproteine. | |
ES2067256T3 (es) | Peptidos biologicamente activos que contienen d-2-alquiltriptofano. | |
DK0466175T3 (da) | Porcint CNP-gen og præcursor-protein | |
DE69230418D1 (de) | GRF-Analoge (Growth Hormone Releasing Factors) | |
NO882454L (no) | Plasminogen-aktivator. | |
AR241800A1 (es) | Procedimiento para preparar compuestos de eglina y procedimiento para obtener preparados farmaceuticos que incluyan a dichos compuestos de eglina como agente activo. | |
AU682638B2 (en) | Peptide, bronchodilator and blood flow ameliorant | |
EP0292257A3 (en) | Peptides having anf activity | |
ES2053535T3 (es) | Derivados heterociclicos de cinco miembros de n,n'-diacilhidrazinas n' sustituidas. | |
ES2051939T3 (es) | Heteroaromatos fenoxialquilsubstituidos, procedimientos para su obtencion y su empleo para la lucha contra las pestes. | |
ES2062006T3 (es) | Un psti humano modificado. | |
EP0687685A4 (en) | PHYSIOLOGICALLY ACTIVE PEPTIDES | |
ZA882641B (en) | Human rhinovirus peptides | |
SE9002384D0 (sv) | Derivat av baklobshormoner |